INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 158 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2021. The put-call ratio across all filers is 1.46 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $158,000 | -65.7% | 11,469 | -59.4% | 0.01% | -63.2% |
| Q1 2022 | $460,000 | -8.2% | 28,279 | -8.1% | 0.02% | +5.6% |
| Q4 2021 | $501,000 | +61.1% | 30,780 | +47.0% | 0.02% | +80.0% |
| Q3 2021 | $311,000 | -34.8% | 20,934 | -12.4% | 0.01% | -9.1% |
| Q2 2021 | $477,000 | -13.4% | 23,894 | 0.0% | 0.01% | -15.4% |
| Q1 2021 | $551,000 | +190.0% | 23,894 | +211.0% | 0.01% | +225.0% |
| Q4 2020 | $190,000 | -44.4% | 7,683 | -7.0% | 0.00% | -50.0% |
| Q3 2020 | $342,000 | +25.7% | 8,257 | +45.7% | 0.01% | +33.3% |
| Q2 2020 | $272,000 | +23.1% | 5,669 | +61.8% | 0.01% | +20.0% |
| Q1 2020 | $221,000 | – | 3,504 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |